alexa Targeting CNS Protein Kinase As Therapeutics For Neurodegenerative Diseases
ISSN: 2150-3494

Chemical Sciences Journal
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th European Chemistry Congress
May 11-13, 2017 Barcelona, Spain

Jung-Mi Hah
Hanyang University, Republic of Korea
Posters & Accepted Abstracts: Chem Sci J
DOI: 10.4172/2150-3494-C1-009
Abstract
The development of protein kinase inhibitors is becoming increasingly important in the development of drugs for peripheral diseases, while protein kinase targets in CNS diseases are rarely developed due to the difficulties of common CNS drug discovery. However, a number of protein kinases are being studied as targets for brain diseases. When developing them, the nature of lowmolecular inhibitors - the molecular design that considers cytochrome P450-mediated metabolism, must be accompanied by blood. brain barrier permeability. Degenerative brain diseases and ischemic brain diseases, which are typical brain diseases, are directly caused by brain cell death, but they are recognized as a result of intracellular signal transduction. Therefore, protein kinase Has begun to be studied. The c-Jun N-terminal kinase (JNK) pathway in the MAPK pathway, which is a representative cell signaling system that regulates cell death, has been verified as a target in relation to many diseases. In particular, JNK3 isoform is expressed in brain tissue The distribution is concentrated, and the connection with neuronal death has been studied extensively.In this study, we have developed a low-molecular-weight inhibitor that can regulate its function by molecular targeting of JNK3 (c-Jun N-terminal kinase), which is considered to play a key role in the brain cell death mechanism of degenerative brain disease , And to conduct a study on structural optimization focusing on improvement of BBB permeation structure of existing lead material.
Biography

Jung-Mi Hah has completed her PhD at the age of 32 years from Northwestern University and postdoctoral studies from Albert Einstein College of Medicine. She is the director of graduate school of Pharmacy at Hanyang University. She has published more than 40 papers in reputed bioorganic and medicinal chemistry journals.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords